Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements

21 December 2021

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQTM (infigratinib) in Canada

21 December 2021

The 3rd Sustainability Report confirms IBSA’s commitment to the well-being of the Person

20 December 2021

BAK publication “The Importance of the Pharmaceutical Industry for Switzerland”

9 December 2021

Helsinn Achieves Carbon Neutrality

6 December 2021

Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)

2 December 2021

Intervista al Presidente FIT Giorgio Calderari, Falò RSI La 1, giovedì 25 novembre 2021

26 November 2021

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

19 November 2021

Farma Industria Ticino in Milan for CPhI 2021, 9-11 November 2021

15 November 2021

Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

12 October 2021